Company
eve Sleep PLC
LON:EVE
We believe in the perfect start. Every great day starts the night before. Good sleep and great starts are too important to be elitist. For too long, mattresses have been sold through expensive stores at massively inflated prices. So we set out to create eve. A mattress that is simply beautiful and beautifully simple, and available to everyone at a surprisingly fair price.
113 stories · page 1 of 2
Archive
Small Cap Feast - Evgen Pharma, Feedback, ImmuPharma, and more...
19th June 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners: No joiners today. Leavers: Mirada Plc (MIRA.L) has left AIM.What’s cooking in the IPO kitchen?**Praetura Gro
Evgen Pharma hails important step in development of SFX-01
The aim of the phase I/Ib study is to understand how SFX-01 works in its new formulation
Eve Sleep bought by Bensons for Bed after going into administration
The AIM-listed company's shares were suspended from trading on AIM yesterday morning
Eve Sleep calls in administrators after unsuccessful sale and funding talks
The sleep wellness brand company had warned last month that it needed further funding after reporting a doubling in pre-tax losses for the first half
Evgen Pharma says new tack with brain cancer programme extends cash runway
The company announced this morning that it will embark on an investigator-sponsored clinical study of SFX-01 in glioblastoma
Evgen Pharma sees forecasts upgraded following major partnership deal with Stalicla
The partnership is for the investigation of Evgen's lead SFX-01 as a potential treatment for autism spectrum disorder and other central nervous system disorders
Archive
Small Cap Feast - Evgen Pharma, I3 Energy, Mosman Oil and Gas, and more...
10 October 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Cooks Coffee Company ltd, an i
Evgen licenses neuro disorder rights of SFX-01 to autism specialist
Evgen and Swiss group Stalicla will collaborate initially on a clinical programme in autism spectrum disorder
Evgen Pharma gets green light to assess new coated tablet form of lead asset
"These approvals will enable us to launch our healthy volunteer study on schedule in the fourth quarter,” said Evgen chief executive, Dr Huw Jones
Archive
Eve Sleep will need a further cash injection as sale talks stall
“We are doing everything possible to manage the business through these incredibly difficult times, whilst speaking with potential investors and strategic partners," Cheryl Calverley, chief executive officer, said
Evgen Pharma and Michigan University to collaborate in colorectal cancer study
This new project is Evgen's fifteenth pre-clinical collaboration
Archive
Small Cap Feast - Evgen Pharma, Franchise Brands, and more...
24 May 2022*A corporate client of Hybridan LLPDish of the dayJoiners:No Joiners Today.Leavers:Clipper Logistics has left the Main Market following a Cash takeover.What’s cooking in the IPO kitchen?According to news reports, The Very Group,
Evgen Pharma launches new collaboration for lead asset
"This will be our 14th academic collaboration and is part of our ongoing strategy," said Evgen CEO Dr Huw Jones
Evgen Pharma expanding its work with the Manchester Breast Centre
The centre is part of the University of Manchester's School of Medical Sciences
Archive
Invinity Energy surges after winning government grant for storage project
A look at the major movers on the London market on Wednesday
Archive
Small Cap Wrap - Ten Lifestyle Group, Plus500, Evgen Pharma and more...
Ten Lifestyle Group 116.5p £97.3m (LON:TENG) The technology-enabled, global concierge platform for the world's wealthy and mass affluent, has won a contract with one of Japan's largest wealth management businesses.
Evgen Pharma signs option to review sulforaphane analogues developed by Spanish researchers
The analogues have the potential for differentiation from the company's lead product, SFX-01, in terms of product formulation
Evgen Pharma at a significant value inflexion point, says City broker
The update from finnCap followed progress with the regulators on both sides of the Atlantic
Evgen Pharma makes headway with regulators on both sides of the Atlantic
Chief executive Huw Jones said he was 'delighted' with the progress that has been made with the Medicines and Healthcare products Regulatory Agency here in the UK and the Food and Drug Administration in the US
Evgen Pharma gears up for a busy start to 2022
"The last six months have yielded further positive preclinical data to support the potential of SFX-01 in a number of cancers and an orphan drug designation in the USA for malignant glioma,” said chief executive Dr Huw Jones
Archive
Small Cap Wrap - Emmerson, Enteq Technologies, Evgen Pharma and more...
Evgen Pharma 6.45p £17.7m (LON:EVG) The clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in preclinical models of glioblastoma (GBM) genera
Evgen Pharma welcomes research on lead asset in treatment of rare brain cancer
The update was provided in the scientific journal 'Pharmaceuticals'
Archive
Small Cap Wrap - Urban Logistics, The Stanley Gibbons Group, Tekmar and more...
Tekmar 44.5p £23m (LON:TGP) The provider of technology and services for the global offshore energy markets, is pleased to announce it has successfully delivered the final batch of Cable Protection Systems (CPS) for Ørsted's Hornsea Two Offs
Evgen Pharma hails Auckland study confirming potential efficacy of anticancer drug
In the in vitro experiments, the company said SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously carried out elsewhere
Evgen Pharma’s SFX-01 granted orphan drug designation by FDA for malignant glioma treatment
The drug company said the OD designation is part of a wider strategy to access the US market
Evgen Pharma makes progress on two fronts in the field of cancer
It is making an orphan drug application in the US. Preclinical research, meanwhile, has flagged the potential of SFX-01 in a form of leukaemia
Evgen Pharma to take a closer look at data after COVID-19 study is discontinued
Chief executive, Dr Huw Jones, said he and the team were both surprised and disappointed by the outcome
Evgen Pharma reports full-year results in line with expectations alongside progress on all fronts
“Over the last 12 months Evgen has substantially strengthened its senior team, made considerable progress across all areas of its business, raised significant funding to accelerate the development of its therapeutic programmes and concluded
Evgen Pharma announces progress on two separate cancer programmes
The group is developing treatment for brain and breast tumours
Evgen Pharma appoints new chief medical officer
Evgen is a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome
Evgen Pharma: Johns Hopkins research further assesses the potential of company's drug to treat COVID-19
Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus
Evgen Pharma strengthens executive board as it seeks partnership deals
Dr Helen Kuhlman has held senior roles at Development Bank of Wales, Innovate UK and Chronos Therapeutics Ltd
Archive
Audioboom booms as revenues hit a record
A look at the major movers on the London market on Thursday
Evgen Pharma outlines next steps for COVID trial after positive safety update
As part of the process, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy
Evgen Pharma now has the financial runway to exploit its technology after 'transformative' City fundraiser
SFX-01, the company’s lead compound. has potential applications in cancers, inflammation and acute respiratory distress syndrome
Evgen Pharma recruits over 100 patients for COVID-19 treatment study
The firm said it is an important milestone bringing it a step closer to receiving the initial data from the trial
Evgen Pharma raises funds to accelerate clinical and pre-clinical work
The company said it has raised £10mln through a share placing and will aim to raise an additional £1mln through an open offer to qualifying shareholders
Archive
Proactive news headlines: Evgen Pharma, Learning Technologies, Union Jack Oil, Direct Plus …
A glance at some of the day's highlights from the Proactive Investors newswire
Evgen Pharma says latest data points to the potential of drug candidate to inhibit a range of cancers
The latest research was carried out by Professor Philip Eaton, of Queen Mary University of London
Eve Sleep to focus on French business after strong year
The sleep wellness retailer cut losses by 81% in 2020
Evgen Pharma CEO hails pre-clinical data from lead drug in glioma and glioblastoma models
Work carried out in collaboration with an unnamed but prominent European university showed tumour shrinkage and significantly extended survival times
Evgen Pharma PLC says 56 people recruited to its STAR-COVID 19 trial
Researchers will investigate whether the company's drug, SFX-01, can reduce the severity, or prevent the onset of acute respiratory distress syndrome
Eve Sleep raises forecasts again after TV ads, Black Friday fuel trading momentum
Full-year revenues are expected to be at least £24mln, while the underlying loss should narrow 77% to £2.5mln compared to last year
Searching for safe dividend income among London's blue-chips
There are some thumping dividend yields on offer among the Footsie stocks, many of them too good to be true, which is why we need to apply the Goldilocks method to sorting the good from the "just right"
Archive
Powerhouse Energy shareholders applaud new board appointment
A look at some of the major movers in London on Friday
Eve Sleep expects smaller full-year loss after defensive pandemic performance
Revenue for the year to December 31, 2020, is expected to be at least £22mln
Eve Sleep’s reawakening rests on a thick bed of data
“I would like us to be seen by customers as a sleep wellness business rather than just a mattress brand,” says CEO Cheryl Calverley
Archive
MobilityOne rockets over 1000% on winning MoneyGram Malaysia contract
A look at some of the major movers in London on Wednesday
Archive
Trafalgar Property Group higher as it sells Barnett Wood property
A look at some of the major risers and fallers in London on Wednesday
Eve Sleep sees risk in higher competition from high street re-openings
In a trading update, the bed maker said revenues for the four months to April were in line with expectations, including good trading in May
Eve Sleep confident in ability to cope with coronavirus after cost cutting
The bed maker boasts a low-cost model and has further padding from a net cash position of £7.8mln
Eve Sleep makes major cost cuts to "break even" in fourth quarter
Revenues in core markets fell 19% to £23.8mln, with an underlying (EBITDA) loss of roughly £10.8mln
Evgen crashes as drug doesn't work on strokes
Tests of the SFX-01 drug candidate in patients who had suffered subarachnoid haemorrhage did not meet the clinical target
Archive
Verona Pharma in demand as Jan-Anders Karlsson and Piers Morgan prepare to address investors
A look at the day's major movers, including AFH Financial, Sirius Minerals, Mereo, Evgen Pharma and ECO Animal Health
Eve tries to wake up sluggish revenues with high-energy "rebuild" plan
The ever-troubled mattress maker's shares slumped by 9.2% in Thursday morning trading
Archive
Small cap movers: eve Sleep and Simba opt for separate beds as merger talks collapse
A look back at some of the more interesting stories from the junior market this week
Eve Sleep opts for separate beds as it ends merger talks with Simba Sleep
Eve Sleep also warned that trading has been more challenging due to an uncertain economic outlook and continuing low levels of consumer confidence
Eve Sleep confirms merger talks with rival mattress retailer Simba
Eve Sleep said it is in “very early stage” discussions with Simba but there can be "no certainty” that the talks will result in a deal
eve Sleep cuts interim losses in half but full-year revenue expected to be below guidance
The troubled mattress maker in the middle of a turnaround strategy having ousted its founder and CEO last year following a series of "strategic missteps"
Investments and investor services
FTSE 100 joins other global markets to head lower as trade fears linger
The UK's blue-chip benchmark index closed out around 42 points lower at 7,493
Archive
Easyjet profit warning and Royal Mail's turnaround update eyed
Along with easyJet, there are also company updates due from Royal Mail and Anglo American, plus UK retail sales data
Archive
easyJet tipped to warn on profits amid challenging short-haul airlines market
It looks set to be a busy week of corporate announcements and UK economic data
Archive
Small cap movers: Woodford contagion reaches AIM
A look back at some of this week's more interesting stories from London's junior market
Investments and investor services
Thomas Cook slumps again as debt-for-equity swap or emergency rights issue is expected
A look at the day's major movers, including Future, Capital & Regional, Tiger Resource, Metro Bank, eve Sleep, Maistro and Staffline
eve Sleep shares dive on weaker than expected fundraising
The beds retailer has been forced to backtrack on promises of selling for “significantly higher than the prevailing share price”, with investors buying at a 30% discount at 10p a share
Archive
Small-cap Movers: TomCo Energy hit with suspension as broker resigns citing reputational damage
A look back at some of the more interesting stories from the junior market this week...
eve Sleep lowers 2019 guidance but shares rise on plans to raise £15mln at ‘significant premium’
The mattress firm wants to invest the money into its website and products to generate the kind of rapid growth investors had been expecting
Eve Sleep narrows focus as it looks to put nightmare 18 months behind it
A series of “strategic missteps” meant sales weren’t as good as hoped for in the first half, but a new strategy and CEO have encouraged the market
Archive
Small cap movers: Footasylum gets a kicking after significant cut to 2019 forecasts
A look back at some of the more interesting stories from the junior market over the past week
Eve Sleep nabs Moonpig boss to correct 'strategic mis-steps'
James Sturrock takes over on September 10 to fill the gap created when former CEO Jas Bagniewski departed
Berenberg gives eve Sleep a rude awakening as it downgrades on weak trading update
In a note to clients, the bank said while it still expected the firm to progress toward profitability, revenue growth had been much slower than forecast
Eve Sleep shares plummet as CEO departs following "strategic missteps"
The mattress maker said that despite trading outperforming the broader market, sales had fallen short of expectations
FTSE 100 closes in red as ongoing trade standoff scares investors
The UK blue chip benchmark shed almost 90 points to finish the day at 7,547.
Archive
Housebuilders and retailers take centre stage as slew of firms release latest results
The week ahead will see quarterly results from Sainsbury's and AB Foods, trading updates from Bovis Homes and Persimmon, and full year earnings from SuperDry
eve Sleep reports strong revenue, margin growth on quicker than expected retail roll-out, European expansion
The AIM-listed firm, which floated in May 2017, reported a 132% leap in revenue to £27.7mln for the full-year 2017, up from £12.0mln a year earlier, with its gross profit margin jumping to 57.7% from 48.6% in 2016
Investments and investor services
FTSE 100 can’t hold gains and closes in red as sterling firms
Britain's blue-chip benchmark closed down over nine points, or 0.13% to 7,214..
Archive
Chancellor's Spring Statement unlikely to include big spending plans, says think-tank
The week ahead includes the UK's budget statement and earnings from Morrisons, Prudential, Cairn Energy, Cineworld, Savills, Wetherspoons, Balfour Beatty and Fevertree
Investments and investor services
Parallel Media and Physiomics lead small cap market gainers
Some of the biggest risers and fallers in London on Wednesday